Dow Jones
31 535,51+603,14(+1,95 %)Nasdaq
13 588,83+396,48(+3,01 %)Nikkei 225
29 663,50+697,49(+2,41 %)
Innate Pharma S.A. (IPH.PA)
- Globe Newswire
Number of shares and voting rights of Innate Pharma as of February 1, 2021
Marseille, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH; Nasdaq: IPHA) releases its total number of shares outstanding as well as its voting rights as of February 1, 2021: Total number of shares outstanding:78,989,740 ordinary shares 6,856 Preferred Shares 2016 7,581 Preferred Shares 2017 Total number of theoretical voting rights (1): Total number of exercisable voting rights (2):79,799,621 79,781,046 (1) The total number of theoretical voting rights (or “gross” voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended. The total number of theoretical voting rights includes (i) voting rights attached to AGAP 2016 (2016 Preferred Shares), i.e. 130 voting rights for the AGAP 2016-1 and 111 voting rights for the AGAP 2016-2 and (ii) voting rights attached to AGAP 2017, i.e. 1 voting right per AGAP 2017. (2) The total number of exercisable voting rights (or “net” voting rights) is calculated without taking into account the shares held in treasury by the Company, with suspended voting rights. It is released so as to ensure that the market is adequately informed, in accordance with the recommendation made by the AMF on July 17, 2007. About Innate Pharma: Innate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need. Innate has been a pioneer in the understanding of natural killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca. Headquartered in Marseille, France, with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US. Learn more about Innate Pharma at www.innate-pharma.com Information about Innate Pharma shares: ISIN codeTicker codeLEIFR0010331421Euronext: IPH Nasdaq: IPHA9695002Y8420ZB8HJE29 Disclaimer on forward-looking information and risk factors: This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995.The use of certain words, including “believe,” “potential,” “expect” and “will” and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s commercialization efforts, the Company’s continued ability to raise capital to fund its development and the overall impact of the COVID-19 outbreak on the global healthcare system as well as the Company’s business, financial condition and results of operations. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2019, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country. For additional information, please contact: Investors Innate Pharma Tel.: +33 (0)4 30 30 30 30 investors@innate-pharma.com Media Innate Pharma Tracy Rossin (Global/US) Tel.: +1 240 801 0076 Tracy.Rossin@innate-pharma.comATCG Press Marie Puvieux (France) Tel.: +33 (0)9 81 87 46 72 innate-pharma@atcg-partners.com Attachment 210224 PR Number of shares and voting rights Feb 24 EN
- Globe Newswire
Nouveau nombre d'actions et de droits de vote d'Innate Pharma au 1er février 2021
Marseille, 24 févr. 2021 (GLOBE NEWSWIRE) -- Conformément aux articles L. 233-8 II du Code de Commerce et 223-16 du règlement général de l’Autorité des marchés financiers (l’« AMF »), Innate Pharma SA (la « Société » - Euronext Paris : FR0010331421 – IPH ; Nasdaq : IPHA) publie le nombre d’actions composant son capital social ainsi que le nombre de droits de vote associés au 1er février 2021 : Nombre d’actions composant le capital :78 989 740 actions ordinaires 6 856 Actions de Préférence 2016 7 581 Actions de Préférence 2017 Nombre de droits de vote théoriques (1) : Nombre de droits de vote exerçables (2) : 79 799 621 79 781 046 (1) Le nombre de droits de vote théoriques (ou droits de vote « bruts ») sert de base de calcul pour les franchissements de seuils. Conformément à l’article 223-11 du Règlement Général de l’AMF, ce nombre est calculé sur la base de l’ensemble des actions auxquelles sont attachés des droits de vote, y compris les actions privées de droit de vote. Le nombre de droits de vote théoriques comprend (i) les droits de vote attachés aux AGAP 2016, soit 130 droits de vote par AGAP 2016-1 et 111 droits de vote par AGAP 2016-2 et (ii) les droits de vote attachés aux AGAP 2017, soit 1 droit de vote par AGAP 2017. (2) Le nombre de droits de vote exerçables (ou droits de vote « nets» ) est calculé en ne tenant pas compte des actions auto-détenues par la Société, privées de droit de vote. Il est communiqué pour la bonne information du public, conformément à la recommandation de l’AMF du 17 juillet 2007. À propos d’Innate Pharma : Innate Pharma S.A. est une société de biotechnologies au stade clinique, spécialisée en immuno-oncologie et dédiée à l’amélioration du traitement des cancers grâce à des anticorps thérapeutiques innovants exploitant le système immunitaire. Le large portefeuille d’anticorps d’Innate Pharma inclut plusieurs candidats potentiellement « first-in-class » aux stades clinique et préclinique dans des cancers où le besoin médical est important. Innate Pharma est pionnière dans la compréhension de la biologie des cellules NK et a développé son expertise dans le microenvironnement tumoral et les antigènes tumoraux, ainsi que dans l'ingénierie des anticorps. Son approche innovante lui a permis de construire un portefeuille propriétaire diversifié et de nouer des alliances avec des sociétés leaders de la biopharmacie comme Bristol-Myers Squibb, Novo Nordisk A/S ou Sanofi ainsi qu’un partenariat multi-produits avec AstraZeneca. Basée à Marseille avec une filiale à Rockville (Maryland, Etats-Unis), Innate Pharma est cotée en bourse sur Euronext Paris et sur Nasdaq aux Etats-Unis. Retrouvez Innate Pharma sur www.innate-pharma.com. Informations pratiques : Code ISINCode mnémoniqueLEIFR0010331421Euronext : IPH Nasdaq : IPHA9695002Y8420ZB8HJE29 Avertissement concernant les informations prospectives et les facteurs de risques : Ce communiqué de presse contient des déclarations prospectives, y compris celles au sens du Private Securities Litigation Reform Act de 1995. L'emploi de certains termes, notamment « croire », « potentiel », « s'attendre à » et « sera » et d'autres expressions semblables, vise à identifier des énoncés prospectifs. Bien que la Société considère que ses projections sont basées sur des hypothèses raisonnables, ces déclarations prospectives peuvent être remises en cause par un certain nombre d’aléas et d’incertitudes, ce qui pourrait donner lieu à des résultats substantiellement différents de ceux anticipés. Ces aléas et incertitudes comprennent notamment les incertitudes inhérentes à la recherche et développement, y compris celles relatives à l’innocuité, aux progrès et aux résultats des essais cliniques et des études précliniques en cours ou prévus, aux examens et autorisations d’autorités réglementaires concernant les produits-candidats de la Société, des efforts commerciaux de la Société, la capacité de la Société à continuer à lever des fonds pour son développement et l’impact global de la pandémie de COVID-19 sur les systèmes de santé ainsi que les activités, la situation financière et les résultats de la Société. Pour des considérations supplémentaires en matière de risques et d’incertitudes pouvant faire différer les résultats effectifs, la situation financière, la performance et les réussites de la Société, merci de vous référer à la section « Facteurs de Risques » du Document d’Enregistrement Universel déposé auprès de l’Autorité des marchés financiers (AMF), disponible sur les sites Internet d’Innate Pharma (www.innate-pharma.com) et de l’AMF (www.amf-france.org), et les documents et rapports publics déposés auprès de la Securities and Exchange Commission (SEC) des États-Unis, y compris le rapport annuel sur « Form 20-F » pour l’exercice clos le 31 décembre 2019 et les documents et rapports subséquents déposés auprès de l'AMF ou de la SEC, ou autrement rendus publics, par la Société. Le présent communiqué, et les informations qu’il contient, ne constituent ni une offre de vente ou de souscription, ni la sollicitation d’un ordre d’achat ou de souscription, des actions d’Innate Pharma dans un quelconque pays. Pour tout renseignement complémentaire, merci de contacter : Relations investisseursContacts PresseInnate PharmaInnate PharmaTel. : +33 (0)4 30 30 30 30investors@innate-pharma.comTracy Rossin (Global / US)Tel. : +1 240 801 0076Tracy.Rossin@innate-pharma.com ATCG Press Marie Puvieux (France)Tel. : +33 (0)9 81 87 46 72innate-pharma@atcg-partners.com Pièce jointe 210224 CP Nombre actions et droits de vote Feb 24 FR
- Globe Newswire
Innate Pharma to Participate in the 10th Annual SVB Leerink Global Healthcare Conference
MARSEILLE, France, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that members of its senior management team are scheduled to participate in the following upcoming virtual investor conference: 10th Annual SVB Leerink Global Healthcare ConferenceEvent Date: February 24-26, 2021Fireside Chat: February 24, 2021 at 2:00-2:30 p.m. CET / 8:00-8:30 a.m. ET A live webcast of the fireside chat will be available through the News & Events page of the Investors section of the Company’s website at www.innate-pharma.com. An archived replay of the webcast will be available for approximately 90 days following the presentation. About Innate Pharma: Innate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need. Innate has been a pioneer in the understanding of natural killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca. Headquartered in Marseille, France, with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US. Learn more about Innate Pharma at www.innate-pharma.com Information about Innate Pharma shares: ISIN codeTicker codeLEIFR0010331421Euronext: IPH Nasdaq: IPHA9695002Y8420ZB8HJE29 Disclaimer on forward-looking information and risk factors: This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995.The use of certain words, including “believe,” “potential,” “expect” and “will” and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s commercialization efforts, the Company’s continued ability to raise capital to fund its development and the overall impact of the COVID-19 outbreak on the global healthcare system as well as the Company’s business, financial condition and results of operations. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2019, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country. For additional information, please contact: InvestorsInnate Pharma Tel.: +33 (0)4 30 30 30 30investors@innate-pharma.comMediaInnate Pharma Tracy Rossin (Global/US)Tel.: +1 240 801 0076Tracy.Rossin@innate-pharma.comATCG Press Marie Puvieux (France)Tel.: +33 (0)9 81 87 46 72innate-pharma@atcg-partners.com
